Response to Comments: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells

This document (A58743) is an administrative response to comments regarding MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells and records a title revision. It provides comment period (2020-05-28 to 2020-07-12), notice start (2021-06-10) and effective (2021-07-25) dates, but does not itself define clinical coverage criteria—refer to LCD L38584 effective 2021-07-25 for coverage rules.

"Administrative record: Comment period for LCD DL38584 was 2020-05-28 to 2020-07-12; notice period for LCD L38584 begins 2021-06-10 and becomes effective 2021-07-25; LCD title revised to 'MolDX: Phe..."

Sign up to see full coverage criteria, indications, and limitations.